AbbVie Stock Chart Shows Pocket Pivot Cluster On FDA Breakthrough Therapy

Abbvie stock is a good long-term buy and hold on a “dream-team” pipeline of phase 3 trials.

Summary

  • AbbVie just received breakthrough therapy designation from the FDA for JAK1 inhibitor.
  • The company has a robust pipeline of drugs in phase 3 trials.
  • Over the last 5 years, revenue has been growing by 8.21% per year.
  • AbbVie stock has a bullish pocket pivot cluster with positive Twiggs Money Flow.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Amgen Stock Setup On FDA Approval for Multiple Myeloma

    Amgen stock looks like a good setup as the Twiggs Money Flow breaks into positive territory.

    Summary

  • The FDA has approved Amgen's supplemental Biologics License Application to expand the label of its key drug Xgeva.
  • Amgen stock is in a continuation pattern and the Twiggs Money Flow has just gone positive.
  • Amgen has nearly $39 billion in cash overseas that could be put to use in the United States.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    BioLife Solutions Stock Play On CAR T Revolution

    BioLife Solutions stock has rising large players volume and a rising Twiggs Money Flow as revenue surges higher from the CAR T cell revolution.

    Summary

  • CAR T cell companies need to freeze and store T cells which is what BioLife Solutions does.
  • BioLife Solutions is riding the CAR T cell revolution wave.
  • The global CAR T cell therapy market is projected to expand exponentially at a CAGR of 46.1% from 2019 through 2028.
  • BioLife Solutions stock has rising large players volume and a rising Twiggs Money Flow.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Shire Stock Rising On FDA Filing For New Manufacturing Facility In Georgia

    Shire stock has rising large players volume and Twiggs Money Flow. The company just filed with the FDA for a new manufacturing facility in Georgia.

    Summary

  • Shire has filed its first submission to the FDA for the company's new plasma manufacturing facility in Covington, Georgia.
  • Twiggs Money Flow breaks into positive territory which suggests Shire stock is being accumulated.
  • Shire has incredible revenue growth after the acquisition of Baxalta in mid-2016.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Allergan Stock Curling Up On Rising Large Players Volume

    Allergan stock is a turnaround gambit on the stock being crushed over fears of a Botox competitor. Large players volume is rising and the Twiggs Money Flow just went positive.

    Allergan stock is curling up on rising large players volume. The Twiggs Money Flow just gave a buy signal too.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Abbott Laboratories Stock Gives Pocket Pivot Signals

    Abbott Laboratories stock is uptrending in a continuation pattern. The company beat on earnings and revenue and has since consolidated.

    Abbott Laboratories stock is in a continuation pattern and has given a couple of bullish pocket pivot signals over the last week or so.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Celgene Stock Now Oversold After Miss and Stopped REVOLVE Trial

    Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.

    Celgene stock looks like a good oversold setup. The stock plunged -35% when the news broke that Celgene stopped its phase 3 trial of REVOLVE and lowered guidance for 2020. I think the sell-off that followed is now over.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Sarepta Therapeutics In Strong Uptrend From Exondys 51

    Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.

    Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.

    Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Adamis Pharmaceuticals Could Explode Over 130 Percent

    Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.

    Adamis Pharmaceuticals was given a $10 price target by analysts at B. Riley last week. B. Riley has a Buy rating on the stock. Overall, the stock has no Sell ratings and 3 Buy ratings. The average target price is $10 which represents 138% upside from the current price of $4.20.

    TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Top News Stories November 14 2017

    The day’s top news stories from stocks on the GuerillaStockTrading watch list.
    Continue reading “Top News Stories November 14 2017”